Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
(COPD): A Meta-Analysis of METREX and METREO Patient-Reported
Outcomes, Response to Therapy and Lung Function

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function

Detalhes bibliográficos
Main Authors:	Chapman, K, Pavord, I, Paggiaro, P, Sciurba, F, Bafadhel, M, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S
Formato:	Conference item
Publicado em:	American Thoracic Society 2018

Registos relacionados

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
Por: Bafadhel, M, et al.
Publicado em: (2018)

Mepolizumab for eosinophilic COPD
Por: Sciurba, F, et al.
Publicado em: (2018)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
Por: Pavord, I, et al.
Publicado em: (2017)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Por: Pavord, I, et al.
Publicado em: (2017)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Por: Gunsoy, N, et al.
Publicado em: (2017)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
Por: Shrimanker, R, et al.
Publicado em: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Por: Mkorombindo T, et al.
Publicado em: (2019-08-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
Por: Bel, E, et al.
Publicado em: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Por: Steven W. Yancey, et al.
Publicado em: (2019-09-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Por: Bel, E, et al.
Publicado em: (2014)

Mepolizumab in refractory eosinophilic asthma.
Por: Pavord, I, et al.
Publicado em: (2010)

Mepolizumab treatment in patients with severe eosinophilic asthma.
Por: Ortega, H, et al.
Publicado em: (2014)

Mepolizumab, quality of life, and severe eosinophilic asthma.
Por: Pavord, I
Publicado em: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Por: Ortega, H, et al.
Publicado em: (2016)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Por: Yancey, S, et al.
Publicado em: (2016)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Por: Howell, I, et al.
Publicado em: (2024)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Por: Shrimanker, R, et al.
Publicado em: (2017)

Eosinophils in COPD: just another biomarker?
Por: Bafadhel, M, et al.
Publicado em: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Por: Imran Howell, et al.
Publicado em: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Por: Terufumi Shimoda, et al.
Publicado em: (2017-07-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Por: Shrimanker, R, et al.
Publicado em: (2017)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
Por: Ian D. Pavord, et al.
Publicado em: (2022-05-01)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
Por: Moran, AM, et al.
Publicado em: (2020)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
Por: Haldar, P, et al.
Publicado em: (2009)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Por: Wechsler, M, et al.
Publicado em: (2017)

Treatment of eosinophilic myositis with mepolizumab
Por: Saadia Waheed, et al.
Publicado em: (2018-01-01)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
Por: Prazma CM, et al.
Publicado em: (2021-06-01)

GLUCOLD, eosinophils and chronic obstructive pulmonary disease
Por: Pavord, I
Publicado em: (2018)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
Por: Mi-Kyeong Kim, et al.
Publicado em: (2021-03-01)

Copd in the ed: eosinophils, treatment and outcomes, data from the pre-award study
Por: Russell, R, et al.
Publicado em: (2016)

Characterising non-eosinophilic COPD
Por: Hambleton, K, et al.
Publicado em: (2015)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
Por: Menzella F, et al.
Publicado em: (2016-06-01)

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.
Por: Bafadhel, M, et al.
Publicado em: (2014)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
Por: Moran, A, et al.
Publicado em: (2020)

Chronic obstructive pulmonary disease (COPD) and COPD-like phenotypes
Por: Spyridon Fortis, et al.
Publicado em: (2024-04-01)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
Por: Frank C. Albers, et al.
Publicado em: (2019-07-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
Por: Chio Sakai, et al.
Publicado em: (2024-07-01)

Investigating blood eosinophil count thresholds in patients with COPD
Por: Russell, R, et al.
Publicado em: (2018)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
Por: Ravi Ranjan Pradhan, et al.
Publicado em: (2019-01-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
Por: Ryota Otoshi, et al.
Publicado em: (2020-03-01)